Aspirin Dosing and Platelet Phenotype in Pregnancy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:
• Pregnant people prior to 17 weeks
• Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
• Age 18-50 years
• Singleton viable gestation
• Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.
Locations
United States
New York
NYU Langone Health
RECRUITING
New York
Contact Information
Primary
Christina A. Penfield, MD, MPH
Christina.Penfield@nyulangone.org
646-754-2700
Backup
Lucia Muzzarelli
Lucia.Muzzarelli@nyulangone.org
646-754-2760
Time Frame
Start Date: 2026-04-27
Estimated Completion Date: 2028-02-20
Participants
Target number of participants: 30
Treatments
Experimental: Twice daily dosing of Aspirin
Participants will take 81mg Aspirin orally, twice daily (162mg total) for 4 weeks and then return to the dosing regimen as prescribed by the discretion of their treating physician.
Related Therapeutic Areas
Sponsors
Leads: NYU Langone Health